RLX-201, a Novel mTORC1 Inhibitor With Potential to Promote Skin Longevity and Cellular Health
mTORC1 hyperactivity is a key feature of aging fibroblasts and contributes to skin aging. RLX-201 enables selective mTORC1 inhibition while preserving mTORC2 activity, supporting its potential to counteract aging-related skin dysfunction and promote skin longevity. Treatment with RLX-201 can rejuvenate the fibroblasts increasing their functionality.
Authors
- Doris Day (ORCID: https://orcid.org/0000-0002-8773-479X)
- Manpreet Randhawa (ORCID: https://orcid.org/0000-0003-3804-305X)
- Krzysztof Bojanowski (ORCID: https://orcid.org/0000-0001-8692-050X)
- Rahul Mehta (ORCID: https://orcid.org/0000-0002-7613-5847)
- Teresa Ferraro (ORCID: https://orcid.org/0009-0005-7050-2246)
- Zhen Fang Huang Cao
Institutions
- NYU Langone Health (US)
- Seralogix (United States) (US)
- Sadick Dermatology (US)
- Sunny BioDiscovery (United States) (US)
Publication Details
- Journal
- Dermatologic Surgery
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1097/dss.0000000000004805
- Primary Topic
- Skin Protection and Aging
- Type
- article
- Field-Weighted Citation Impact
- 0.00